Swiss Chemicals Stock News

As European markets continue to show optimism with major stock indexes rising, investors are increasingly focused on the strengthening eurozone economy and favorable interest rate conditions. In this environment, dividend stocks can offer a stable income stream, making them an attractive option for those looking to capitalize on the current economic momentum while potentially benefiting from regular payouts.

Avolta AG ( VTX:AVOL ), is not the largest company out there, but it saw a double-digit share price rise of over 10% in...

Forbo Holding AG ( VTX:FORN ), is not the largest company out there, but it saw a significant share price rise of 34...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

There wouldn't be many who think CALIDA Holding AG's ( VTX:CALN ) price-to-sales (or "P/S") ratio of 0.4x is worth a...

Most readers would already be aware that Ascom Holding's (VTX:ASCN) stock increased significantly by 16% over the past...

DKSH Holding AG recently received official validation from the Science Based Targets initiative that its near-term and net-zero emissions targets align with climate science and the Paris Agreement, confirming deep reductions in Scope 1, 2, and 3 emissions and a commitment to net-zero across its value chain by 2050. This independent endorsement strengthens DKSH’s sustainability positioning, underscoring how its efforts in transport optimization, renewable electricity, fleet electrification,...

If you are wondering whether Roche Holding's current share price really reflects its quality and prospects, you are not alone; many investors are asking the same question. The stock last closed at CHF 345.70, with returns of 1.9% over 7 days, 7.9% over 30 days, 6.2% year to date, 33.0% over 1 year and 31.0% over 3 years. This naturally raises questions about how much of this performance is already priced in. Recent coverage has focused on Roche Holding's position as a major global...

Earlier this month, UBS Group AG completed two US$1.50 billion fixed-coupon, perpetual, callable subordinated Eurobond issues, while simultaneously intensifying its public opposition to proposed tighter Swiss banking capital rules following the Credit Suisse collapse. By arguing that fully capitalizing foreign subsidiaries and raising capital buffers could add about US$1.70 billion in annual costs and threaten its business model, UBS has put the trade-off between financial stability and...

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

Sika AG recently reported preliminary 2025 results showing CHF 11.20 billion in sales, modest growth in local currencies but a reported sales decline due to a strong Swiss franc, softer construction demand in markets such as China and the US, and an earnings margin outlook now only slightly above 19% excluding one-off restructuring costs. Management launched the “Fast Forward” cost and investment program, including up to 1,500 job cuts and targeted annual savings of CHF 150–200 million by...

Key Insights Burkhalter Holding's estimated fair value is CHF115 based on 2 Stage Free Cash Flow to Equity With CHF136...

Key Insights Arbonia's significant individual investors ownership suggests that the key decisions are influenced by...

It is hard to get excited after looking at BKW's (VTX:BKW) recent performance, when its stock has declined 4.7% over...

It's not a stretch to say that Komax Holding AG's ( VTX:KOMN ) price-to-sales (or "P/S") ratio of 0.5x right now seems...

Chocoladefabriken Lindt & Sprüngli (SWX:LISN) issued fresh earnings guidance, signaling a planned 20 to 40 basis point annual improvement in operating profit margin from a 16.2% base, beginning with a modest uplift in 2025. See our latest analysis for Chocoladefabriken Lindt & Sprüngli. The updated earnings guidance lands after a mixed year for the shares. The 1 year total shareholder return of 17.58% contrasts with a 90 day share price return decline of 11.76%, suggesting shorter term...

In January 2026, Swiss Federal Railways (SBB) awarded a joint venture between Implenia and Marti five of six lots for the MehrSpur Zurich–Winterthur rail expansion, giving Implenia an approximately CHF 830 million share of a roughly CHF 1.70 billion, decade-long infrastructure program. This long-duration, technically complex tunneling and station-upgrade mandate aligns closely with Implenia’s focus on large infrastructure projects and could reinforce its positioning in higher-value,...

In recent days, Novartis and SciNeuro Pharmaceuticals announced a worldwide licensing and collaboration deal to develop an amyloid beta antibody program for Alzheimer’s disease, while Novartis also unveiled plans for a new radioligand therapy manufacturing facility in Winter Park, Florida, as part of its multi-billion-dollar US investment. Together, these moves highlight how Novartis is pairing early-stage neuroscience innovation with expanded US radioligand production to deepen its...

Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...

Swisscom AG's ( VTX:SCMN ) price-to-earnings (or "P/E") ratio of 24.3x might make it look like a sell right now...

Tecan Group AG has released unaudited preliminary results for fiscal 2025, reporting second-half sales growth of 0.4% in local currencies but a 5.2% decline in Swiss francs to CHF 443.0 million, with full-year sales down 1.6% in local currencies and 5.5% in Swiss francs to CHF 882.5 million versus 2024. The return to modest second-half growth, despite a full-year sales contraction, highlights a possible turning point in demand momentum amid currency headwinds and lingering operational...

Why the lucerastat data matters for Idorsia shares Idorsia (SWX:IDIA) just put fresh Phase 3 and long term lucerastat data for Fabry disease into the public domain, with kidney and cardiac outcomes now in focus after the study missed its primary pain endpoint. For you as a shareholder or potential investor, this shifts attention to how lucerastat might fit into Idorsia's broader rare disease pipeline, future regulatory discussions, and the perceived value of its R&D portfolio. See our latest...

Earlier in January 2026, Swiss Re AG promoted Christophe Heck to market head Life Health for France, BeNeLux and Switzerland, with Heck now leading the Life Health reinsurance team from Zurich after more than a decade in the industry. This appointment places an experienced leader over several of Swiss Re’s core European Life Health markets, potentially influencing how the group prioritizes growth, risk selection and client engagement across the segment. We’ll now explore how Christophe...

If you have been wondering whether Sika shares are now offering value or still look expensive, this breakdown will help you put the current price into context before you commit fresh capital. Sika shares last closed at CHF149.10, with returns of an 8.7% decline over 7 days, a 6.7% decline over 30 days, an 8.9% decline year to date, and a 30.8% decline over 1 year, adding to a 39.6% decline over 3 years and a 35.0% decline over 5 years. Recent coverage around Sika has focused on its position...